Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Apellis Pharmaceuticals Inc

APLS
Current price
47.53 USD +0.01 USD (+0.02%)
Last closed 47.51 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 6 243 705 344 USD
Yield for 12 month -42.34 %
1Y
3Y
5Y
10Y
15Y
APLS
21.11.2021 - 28.11.2021

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

82.8 USD

P/E ratio

Dividend Yield

Current Year

+396 591 000 USD

Last Year

+75 422 000 USD

Current Quarter

+146 377 000 USD

Last Quarter

+99 182 000 USD

Current Year

+336 377 000 USD

Last Year

+69 786 000 USD

Current Quarter

+126 465 000 USD

Last Quarter

+76 772 000 USD

Key Figures APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -515 336 992 USD
Operating Margin TTM -57.74 %
PE Ratio
Return On Assets TTM -41.73 %
PEG Ratio
Return On Equity TTM -290.14 %
Wall Street Target Price 82.8 USD
Revenue TTM 396 591 008 USD
Book Value 1.63 USD
Revenue Per Share TTM 3.34 USD
Dividend Share
Quarterly Revenue Growth YOY 545.9 %
Dividend Yield
Gross Profit TTM 69 786 000 USD
Earnings Share -4.45 USD
Diluted Eps TTM -4.45 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -133.29 %

Dividend Analytics APLS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 15.1377
Price Sales TTM 15.7466
Enterprise Value EBITDA -12.123
Price Book MRQ 32.0979

Financials APLS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators APLS

For 52 weeks

19.83 USD 94.75 USD
50 Day MA 61.5 USD
Shares Short Prior Month 10 591 406
200 Day MA 53.41 USD
Short Ratio 7.76
Shares Short 10 439 851
Short Percent 10.05 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics